International Journal of Pharmaceutical and Phytopharmacological Research
ISSN (Print): 2250-1029
ISSN (Online): 2249-6084
Publish with eIJPPR Submission
2020   Volume 10   Issue 5

Treatment with Sofosbovir+Daclatasvir in HIV/HCV Co-Infected Patients: A Real-World Perspective
Download PDF


Azadeh Beiglarzadeh, Saman Soleimanpour, Mahbubeh Haddad, Mahnaz Arian, Amin Bojdy
Citation
Vancouver
Beiglarzadeh A, Soleimanpour S, Haddad M, Arian M, Bojdy A. Treatment with Sofosbovir+Daclatasvir in HIV/HCV Co-Infected Patients: A Real-World Perspective. Int j pharm phytopharm res. 2020;10(5):285-289. https://doi.org/10.51847/H59gSPo6mA
APA
Beiglarzadeh, A., Soleimanpour, S., Haddad, M., Arian, M., & Bojdy, A. (2020). Treatment with Sofosbovir+Daclatasvir in HIV/HCV Co-Infected Patients: A Real-World Perspective. International Journal Of Pharmaceutical And Phytopharmacological Research, 10(5),285-289. https://doi.org/10.51847/H59gSPo6mA
Download citation:   EndNote   RIS
Article Link:
Abstract

Determining the effect of new antiviral (Direct-Acting Antivirals; DAAs) medicines, such as SOF + DCV on HCV treatment in HIV/HCV co-infected patients. HIV/HCV co-infected patients were treated with SOF + DCV combination for 12 weeks and the drug dosage was adjusted according to ART in case needed. APRI, FIB4 Index and MELD Score formulas were used to examine the effect of treatment on the degree of liver fibrosis and HCV RNA PCR was performed to evaluate the response to 12-week treatment after the completion of the treatment.

Twenty-four male patients with the mean age of 44±7.73 years were enrolled in the study with 58.3% having a history of unprotected sexual contact and 100% having a history of injectable drug use. The mean HCV viral load at the baseline was 6.3Log10 IU/ML and 5 cases having undetectable viral load were excluded. Seven patients had GT1, 6 patients had GT3 and other cases were not detectable. HCV RNA PCR was undetectable in 18 patients 12 weeks after the treatment. Moreover, the decrease in ALT and AST (P= 0.001), the increase in platelet count (P= 0.016), and the increase in cr (P= 0.032) were significant, which partially justified the reduction in liver fibrosis using non-invasive methods. Twelve weeks after treatment, 19 patients were tested for HCV RNA PCR, the HCV viral load was not detectable in 18 patients and reached to SVR12 (sustained virologic response) rate 94.7%. According to the current study, treatment with SOF + DCV combination was associated with SVR12 rate 94.7%. Thus, SOF + DCV combination can now be used as an effective medicine in the treatment of all hepatitis C genotypes in HIV/HCV co-infected patients


International Journal of Pharmaceutical and Phytopharmacological Research
© 2021 All rights reserved